Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Nestle Health Science

- PMLiVE

EU authorises Aimmune’s peanut allergy treatment Palforzia

Approval in the EU comes nine months after US authorisation

- PMLiVE

Nestlé is set to acquire Aimmune in deal worth $2.6bn

Aimmune’s Palforzia therapy is the only FDA-approved peanut allergy drug

- PMLiVE

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia

- PMLiVE

Aimmune’s Palforzia is first peanut allergy drug cleared in US

Shares in the Nasdaq-listed biotech have spiked

- PMLiVE

DBV refiles peanut allergy immunotherapy in the US

Follows initial manufacturing concerns

- PMLiVE

Nestlé Health Science invests $145m in food allergy biotech

Aimmune Therapeutics' lead product is a phase III peanut allergy treatment

- PMLiVE

Nestlé Health Science buys medical device firm

Acquisition of UK's Phagenesis expected to be completed by 2019

Nestlé begins mHealth trial

Launches trials in healthly ageing research programme

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links